THANG ĐIỂM REVEAL LITE 2.0 TRONG TIÊN LƯỢNG NGƯỜI BỆNH TĂNG ÁP LỰC ĐỘNG MẠCH PHỔI NHÓM 1

Abstract

Objectives: To determine the value of the REVEAL Lite 2.0 score in predicting major events after 6 months to 1 year in patients with pulmonary arterial hypertension (PAH). Methods: A cross-sectional and longitudinal study to follow-up of events in 50 PAH patients in three risk groups based on the REVEAL Lite 2.0 scale at Vietnam National Cardiology Institute, Bach Mai hospital from January 2021 to October 2022. Results: The mean age 36,8 ± 14,2 with 85% of the patients were female, 58% cause of PAH due to congenital heart disease. Scoring based on the REVEAL Lite 2.0 scale (including: WHO-FC, heart rate, systolic blood pressure, NT-proBNP and eGFR and 6-minute walk test) patients are divided into three risk group: Low (18%), Intermediate (26%), High (56%). The mean values of 6 minutes walk test is 209,21 ± 86,5 meters; NT-proBNP is 219,5±213,5 pmol/L; eGFR is 80,6± 24,17 ml /p/m³. The value of NT-proBNP and eGFR are independently correlated with the survival prognosis of patients in the study. The rates of total in-hospital events in the low, intermediate, and high-risk groups were 21,4%, 15,4%, and 0%. The mean number of hospital readmission per month in the three high, medium, and low risk groups was statistically significant difference. with p<0,05. The mortality rate after 6 months to 1 year of follow-up in the high-risk group was 16%, and in the others were 0%. Conclusion: The risk stratification of patients with PAH by the REVEAL Lite 2.0 scale is easy to apply and is valuable early and long prognosis in patient PAH.